ConductScience.org, home

Paper26057738

Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.

Tang W and 7 others. PLoS One, 2015. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis. Papers, record 26057738. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26057738

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.
PubMed
Journal
PLoS One
PubMed
Year
2015
PubMed
Publication types
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.34
iCite
Revised in PubMed
2018-11-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tang WWei
2Chen LLun
3Zheng RRuohui
4Pan LLingxiao
5Gao JJin
6Ye XXigang
7Zhang XXiaoshen
8Zheng WWenbo

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Chemical and Drug Induced Liver InjuryMajor topic
Hepatitis BMajor topic
LamivudineMajor topic
Reverse Transcriptase InhibitorsMajor topic
Antineoplastic Agents
Female
Humans

Source PubMed

Download CSV of topics

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122973419Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Ther Adv Gastroenterol2012https://conductscience.org/library/papers/22973419PubMed
217256718Chronic hepatitis B.Hepatology2007https://conductscience.org/library/papers/17256718PubMed
318302293A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.Hepatology2008https://conductscience.org/library/papers/18302293PubMed
414738558High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.J Viral Hepat2004https://conductscience.org/library/papers/14738558PubMed
59620341Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Hepatology1998https://conductscience.org/library/papers/9620341PubMed
611753968Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients.Cancer2001https://conductscience.org/library/papers/11753968PubMed
710502254Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.J Med Virol1999https://conductscience.org/library/papers/10502254PubMed
82629023Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients.Q J Med1989https://conductscience.org/library/papers/2629023PubMed
910707871Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.J Hepatol2000https://conductscience.org/library/papers/10707871PubMed
1023073741Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.Breast Cancer2014https://conductscience.org/library/papers/23073741PubMed
1111722410Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.Br J Haematol2001https://conductscience.org/library/papers/11722410PubMed
1211003630Long-term therapy of chronic hepatitis B with lamivudine.Hepatology2000https://conductscience.org/library/papers/11003630PubMed
1315609123Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.Breast Cancer Res Treat2004https://conductscience.org/library/papers/15609123PubMed
1421821601
Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.
Jpn J Clin Oncol2011https://conductscience.org/library/papers/21821601PubMed
158781348Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.Hepatology1996https://conductscience.org/library/papers/8781348PubMed
1611055239Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.J Med Virol2000https://conductscience.org/library/papers/11055239PubMed
1715566502Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.Liver Int2004https://conductscience.org/library/papers/15566502PubMed
1810458258Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem.J Clin Oncol1999https://conductscience.org/library/papers/10458258PubMed
1921285992Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.Br J Cancer2011https://conductscience.org/library/papers/21285992PubMed
209636828Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma.Ann Oncol1998https://conductscience.org/library/papers/9636828PubMed

See all 28 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42516138Establishment of prognostic nomogram in cervical cancer with hepatitis B virus infection: a retrospective study.Front Oncol2026https://conductscience.org/library/papers/42516138PubMed
34621337COVID-19 Pandemic Impact on Cord Blood Collection for Stem Cell Use and Actual Perspectives.Maedica (Bucur)2021https://conductscience.org/library/papers/34621337PubMed
29637482Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.Clin Rheumatol2018https://conductscience.org/library/papers/29637482PubMed
27291888Prevention of Hepatitis B reactivation in the setting of immunosuppression.Clin Mol Hepatol2016https://conductscience.org/library/papers/27291888PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/26057738

GET https://conductscience.org/api/papers/v1/26057738/references?page=2